The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
United States: The U.S. government operates border preclearance facilities at several ports and airports in foreign territory. They are staffed and operated by U.S. Customs and Border Protection officers. Travellers pass through the U.S. Immigration and Customs, Public Health, and Agriculture inspections before boarding their aircraft, ship, or train. This process is intended to streamline border procedures, reduce congestion at ports of entry, and facilitate travel between the preclearance location and American airports that are not equipped to handle international travellers. These facilities are present at the majority of major Canadian airports, as well as selected airports in Bermuda, Aruba, the Bahamas, Abu Dhabi and Ireland. Facilities located in Canada accept NEXUS cards and United States Passport cards (land/sea entry only) in place of passports. A preclearance facility is currently being planned at Dubai International Airport. Citizens of the Bahamas who enter United States through either of the two preclearance facilities in that country enjoy an exemption from the general requirement to hold a visa as long as they can sufficiently prove that they do not have a significant criminal record in either the Bahamas or the U.S. All Bahamians applying for admission at a port-of-entry other than the preclearance facilities located in Nassau or Freeport International airports are required to have a valid visa. Preclearance facilities are also operated at Pacific Central Station, the Port of Vancouver, and the Port of Victoria in British Columbia.
The plant is stemless and usually produces several rosettes consisting of wiry, lax, grasslike, flattened leaves. Leaves, up to 1 meter long and 12mm wide (3+1⁄3 feet x ~1⁄2 inch), have margins bearing many small, close-together, skin-cutting teeth. Inflorescences are panicle type and up to 35cm long (~14 inches) atop scapes up to 70cm tall (~2+1⁄3 feet) Flowers are functionally male or female, the males with larger stamens, the females with better developed pistils, but both types have both stamens and pistils. Flowers have six yellow-green tepals up to 2.5mm long (~2+1⁄3 inch) Fruits are winged, slightly inflated capsules up to 10 mm tall and 11mm wide (~1⁄3 inch).
== Use == So far, biomass-based production of industrial microalgae has been widely applied in the fields from food and feed to high-value chemicals for pharmaceutical and ecological applications. Although the commercial cultivation of microalgae became increasingly popular, only algal biomass is processed to current products, while huge volumes of algae-free media are unexploited in flow through cultures and after biomass harvesting of batch cultures. Medium recycling to save culturing costs faces the big risk of growth inhibition. High volumes of spent media give rise to environmental pollution and cost of water and nutrition supply in cultivation when the media are discarded directly to the environment. Therefore the application of recycling methods motivated by the simultaneous generation of high value products from spent medium bears potential in commercial and environmental perspectives.
Sources: en.wikipedia.org
A broader survey of Drosophila de novo proteins likewise found that most differ from conserved proteins in predicted properties, but that a subset are predicted to adopt known folds and participate in specific cellular processes. Inference from prediction tools requires caution because many predictors were trained and benchmarked primarily on conserved, globular proteins, and their performance can be biased for short or low-homology sequences. In particular, disorder predictions can be sensitive to parameter choices, and different structure predictors (including alignment-based and protein language model approaches) may disagree on de novo proteins and yield low-confidence models. Comparisons of "newly born" orphan proteins to "never born" random polypeptides using multiple deep-learning structure predictors similarly reported that predicted models are often of low quality while still allowing limited qualitative comparisons across sequence sets.
The operating room time required to harvest, refine, and emplace fat to the breasts is greater than the usual 2-hour OR time; the usual infiltration time was approximately 2 hours for the first 100 cm3 volume, and approximately 45 minutes for injecting each additional 100 cm3 volume of breast-filler fat. The technique for injecting fat grafts for breast augmentation allows the plastic surgeon great control in sculpting the breasts to the required contour, especially in the correction of tuberous breast deformity. In which case, no fat-graft is emplaced beneath the nipple-areola complex (NAC), and the skin envelope of the breast is selectively expanded (contoured) with subcutaneously emplaced body-fat, immediately beneath the skin. Such controlled contouring selectively increased the proportional volume of the breast in relation to the size of the nipple-areola complex, and thus created a breast of natural form and appearance; greater verisimilitude than is achieved solely with breast implants. The fat-corrected, breast-implant deformities, were inadequate soft-tissue coverage of the implant(s) and capsular contracture, achieved with subcutaneous fat-grafts that hid the implant-device edges and wrinkles, and decreased the palpability of the underlying breast implant. Furthermore, grafting autologous fat around the breast implant can result in softening the breast capsule.
=== Risk factors === The use of antipsychotics as well as how this class of medications is used is one of the most common risk factors for NMS. Use of high-potency antipsychotics, a rapid increase in the dosage of antipsychotics, use of long-acting forms of antipsychotics (such as haloperidol) or injectable formulations, or using multiple antipsychotics are all known to increase the risk of developing NMS. Dehydration is a risk factor for the development of NMS. There appears to be no relationship between duration of therapy and the development of NMS. Use of the following agents is most commonly associated with the development of NMS:
The widespread smoking of cigarettes in the Western world is largely a 20th-century phenomenon. By the late 19th century cigarettes were known as coffin nails but the link between lung cancer and smoking was not established until the 20th century. German doctors were the first to make the link, and it led to the first antitobacco movement in Nazi Germany.
Sources: en.wikipedia.org
=== Microvascular effects (retinopathy) === Initial trials noted an increase in complications related to diabetic retinopathy. Subsequent analyses have clarified that this early worsening of pre-existing retinopathy is a secondary effect caused by the rapid and robust drop in blood glucose levels, rather than a direct toxic effect of semaglutide on the eyes.
== History of the term == Homochirality was introduced by Lord Kelvin in 1904, the year that he published his Baltimore Lecture of 1884. Kelvin used homochirality as a relationship between two molecules, i.e. two molecules are homochiral if they have the same chirality. Homochiral has been used in the same sense as enantiomerically pure. This is permitted in some journals (but not encouraged), its meaning in these journals being the preference of a process or system for a single optical isomer of a pair.
Oxycodone/aspirin (trade name Percodan) is a combination drug marketed by Endo Pharmaceuticals. It is a tablet containing a mixture of 325 mg (5 grains) of aspirin and 4.8355 mg of oxycodone HCl (equivalent to 4.3346 mg of oxycodone as the free base); it is an opioid/non-opioid combination used to treat moderate to moderately severe pain. The safety of the combination during pregnancy has not been established, although aspirin is generally contraindicated during pregnancy, and the drug has been placed in pregnancy category D. Inactive ingredients include D&C Yellow 10, FD&C Yellow 6, microcrystalline cellulose, and corn starch. Percodan was first marketed by DuPont Pharmaceuticals and prescribed in the United States in 1950. Once a widely prescribed painkiller, it has largely been replaced by alternative oxycodone compounds containing paracetamol (acetaminophen) instead of aspirin, such as Percocet.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.